CL2019003789A1 - Plasminogen treatment of conditions associated with pai-1 overexpression. - Google Patents
Plasminogen treatment of conditions associated with pai-1 overexpression.Info
- Publication number
- CL2019003789A1 CL2019003789A1 CL2019003789A CL2019003789A CL2019003789A1 CL 2019003789 A1 CL2019003789 A1 CL 2019003789A1 CL 2019003789 A CL2019003789 A CL 2019003789A CL 2019003789 A CL2019003789 A CL 2019003789A CL 2019003789 A1 CL2019003789 A1 CL 2019003789A1
- Authority
- CL
- Chile
- Prior art keywords
- pai
- overexpression
- conditions associated
- plasminogen
- treatment
- Prior art date
Links
- 102000013566 Plasminogen Human genes 0.000 title abstract 3
- 108010051456 Plasminogen Proteins 0.000 title abstract 3
- 230000002018 overexpression Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 abstract 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 abstract 2
- 208000032594 Vascular Remodeling Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
LA INVENCIÓN SE REFIERE AL USO DEL PLASMINÓGENO, UNA VARIANTE DE ESTE, O UN ANÁLOGO QUE TIENE UNA ACTIVIDAD DE PLASMINÓGENO PARA LA PREVENCIÓN O TRATAMIENTO DE UNA AFECCIÓN O UNA ENFERMEDAD QUE SE CARACTERIZA CON UN MAYOR NIVEL DE PAI-1. LAS AFECCIONES Y ENFERMEDADES QUE SE CARACTERIZAN CON UN MAYOR NIVEL DE PAI-1 SE REAGRUPAN DENTRO DE DOS CATEGORÍAS: LAS ENFERMEDADES ASOCIADAS A UNA CAPACIDAD ALTERADA DE REMODELACIÓN TISULAR Y VASCULAR, Y LOS TRASTORNOS METABÓLICOS Y HORMONALES ASOCIADOS A UN MAYOR NIVEL DE PAI-1.THE INVENTION REFERS TO THE USE OF THE PLASMINOGEN, A VARIANT OF THIS, OR AN ANALOGUE HAVING A PLASMINOGEN ACTIVITY FOR THE PREVENTION OR TREATMENT OF A CONDITION OR A DISEASE THAT IS CHARACTERIZED WITH A HIGHER LEVEL OF PAI-1. THE CONDITIONS AND DISEASES THAT ARE CHARACTERIZED WITH A HIGHER LEVEL OF PAI-1 ARE REAGRUPTED INTO TWO CATEGORIES: DISEASES ASSOCIATED WITH AN ALTERED CAPACITY FOR TISULAR AND VASCULAR REMODELING, AND THE PAI-1-MAJOR METABOLIC NIVEL DISORDERS. .
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523901P | 2017-06-23 | 2017-06-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019003789A1 true CL2019003789A1 (en) | 2020-07-10 |
Family
ID=64737041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019003789A CL2019003789A1 (en) | 2017-06-23 | 2019-12-20 | Plasminogen treatment of conditions associated with pai-1 overexpression. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11826404B2 (en) |
| EP (1) | EP3641888B1 (en) |
| JP (1) | JP2020524689A (en) |
| KR (1) | KR20200019217A (en) |
| CN (1) | CN110831668B (en) |
| AU (1) | AU2018287316B2 (en) |
| BR (1) | BR112019027229A2 (en) |
| CA (1) | CA3068153A1 (en) |
| CL (1) | CL2019003789A1 (en) |
| DK (1) | DK3641888T3 (en) |
| ES (1) | ES2965937T3 (en) |
| FI (1) | FI3641888T3 (en) |
| IL (1) | IL271470B2 (en) |
| MX (1) | MX2019015741A (en) |
| MY (1) | MY203136A (en) |
| RU (1) | RU2020100080A (en) |
| SG (1) | SG11201912813SA (en) |
| TW (1) | TWI868051B (en) |
| WO (1) | WO2018234861A1 (en) |
| ZA (1) | ZA202000280B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11389515B2 (en) | 2016-12-15 | 2022-07-19 | Talengen International Limited | Method for mitigating heart disease |
| TW201822812A (en) | 2016-12-15 | 2018-07-01 | 深圳瑞健生命科學硏究院有限公司 | Method for preventing and treating obesity |
| CA3047181A1 (en) | 2016-12-15 | 2018-06-21 | Talengen International Limited | Method and drug for preventing and treating obesity |
| KR20220137950A (en) * | 2020-02-06 | 2022-10-12 | 탈렌젠 인터내셔널 리미티드 | Methods and drugs for prevention and treatment of multiple sclerosis |
| JP2023518564A (en) * | 2020-03-24 | 2023-05-02 | タレンゲン インターナショナル リミテッド | Methods and Agents for Promoting Degradation of Misfolded Proteins and Aggregates Thereof |
| WO2021190561A1 (en) * | 2020-03-24 | 2021-09-30 | 泰伦基国际有限公司 | Method and drug for treating parkinson's disease |
| TWI868333B (en) * | 2020-03-24 | 2025-01-01 | 大陸商深圳瑞健生命科學研究院有限公司 | A method and drug for treating Alzheimer's disease |
| CN112174979B (en) * | 2020-10-27 | 2021-09-07 | 黑龙江中医药大学 | A kind of medicine for treating polycystic ovary syndrome and preparation method thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5520912A (en) | 1993-07-02 | 1996-05-28 | Immuno Aktiengesellschaft | Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen |
| WO2001036351A2 (en) | 1999-11-19 | 2001-05-25 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists related applications |
| WO2001058476A2 (en) * | 2000-02-11 | 2001-08-16 | The European Molecular Biology Laboratory | Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity |
| GB0509438D0 (en) * | 2005-05-09 | 2005-06-15 | Prometic Biosciences Ltd | Affinity adsorbets for fibrinogen |
| ES2451015T3 (en) * | 2006-08-28 | 2014-03-26 | Omnio Healer Ab | Candidates against infection |
| AU2007290882B2 (en) | 2006-08-28 | 2013-02-21 | Omnio Healer Ab | Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health |
| KR20160035077A (en) * | 2013-08-13 | 2016-03-30 | 사노피 | Antibodies to plasminogen activator inhibitor-1(pai-1) and uses thereof |
| TWI801331B (en) * | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | Plasminogen replacement therapy for plasminogen-deficiency |
| TW201722464A (en) * | 2015-11-10 | 2017-07-01 | 波麥堤克生化科學有限公司 | Plasminogen dosage regimen for wound healing |
| WO2018107695A1 (en) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | Method for preventing and treating kidney fibrosis |
| EP3556395A4 (en) * | 2016-12-15 | 2020-07-22 | Talengen International Limited | Method for preventing and treating pulmonary fibrosis |
| CA3047181A1 (en) * | 2016-12-15 | 2018-06-21 | Talengen International Limited | Method and drug for preventing and treating obesity |
-
2018
- 2018-06-15 TW TW107120839A patent/TWI868051B/en active
- 2018-06-22 JP JP2019570806A patent/JP2020524689A/en active Pending
- 2018-06-22 WO PCT/IB2018/000655 patent/WO2018234861A1/en not_active Ceased
- 2018-06-22 CA CA3068153A patent/CA3068153A1/en active Pending
- 2018-06-22 RU RU2020100080A patent/RU2020100080A/en unknown
- 2018-06-22 DK DK18821458.9T patent/DK3641888T3/en active
- 2018-06-22 AU AU2018287316A patent/AU2018287316B2/en active Active
- 2018-06-22 BR BR112019027229-1A patent/BR112019027229A2/en not_active Application Discontinuation
- 2018-06-22 FI FIEP18821458.9T patent/FI3641888T3/en active
- 2018-06-22 CN CN201880041573.5A patent/CN110831668B/en active Active
- 2018-06-22 MY MYPI2019007619A patent/MY203136A/en unknown
- 2018-06-22 KR KR1020207001617A patent/KR20200019217A/en not_active Ceased
- 2018-06-22 SG SG11201912813SA patent/SG11201912813SA/en unknown
- 2018-06-22 EP EP18821458.9A patent/EP3641888B1/en active Active
- 2018-06-22 ES ES18821458T patent/ES2965937T3/en active Active
- 2018-06-22 MX MX2019015741A patent/MX2019015741A/en unknown
- 2018-06-22 IL IL271470A patent/IL271470B2/en unknown
- 2018-06-22 US US16/625,335 patent/US11826404B2/en active Active
-
2019
- 2019-12-20 CL CL2019003789A patent/CL2019003789A1/en unknown
-
2020
- 2020-01-15 ZA ZA2020/00280A patent/ZA202000280B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3068153A1 (en) | 2018-12-27 |
| EP3641888B1 (en) | 2023-10-11 |
| RU2020100080A (en) | 2021-07-23 |
| SG11201912813SA (en) | 2020-01-30 |
| EP3641888A1 (en) | 2020-04-29 |
| IL271470B1 (en) | 2025-03-01 |
| CN110831668A (en) | 2020-02-21 |
| MX2019015741A (en) | 2020-11-11 |
| AU2018287316A1 (en) | 2020-02-06 |
| TW201904990A (en) | 2019-02-01 |
| AU2018287316B2 (en) | 2024-09-19 |
| WO2018234861A1 (en) | 2018-12-27 |
| TWI868051B (en) | 2025-01-01 |
| DK3641888T3 (en) | 2024-01-02 |
| ZA202000280B (en) | 2021-08-25 |
| IL271470B2 (en) | 2025-07-01 |
| RU2020100080A3 (en) | 2021-11-02 |
| MY203136A (en) | 2024-06-10 |
| ES2965937T3 (en) | 2024-04-17 |
| CN110831668B (en) | 2024-04-12 |
| JP2020524689A (en) | 2020-08-20 |
| KR20200019217A (en) | 2020-02-21 |
| US11826404B2 (en) | 2023-11-28 |
| IL271470A (en) | 2020-01-30 |
| FI3641888T3 (en) | 2023-12-19 |
| BR112019027229A2 (en) | 2020-07-07 |
| EP3641888A4 (en) | 2021-03-10 |
| US20210330761A1 (en) | 2021-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003789A1 (en) | Plasminogen treatment of conditions associated with pai-1 overexpression. | |
| IL280710A (en) | Methods and compositions for the treatment of mitochondrial diseases or and troplasmic disorders | |
| MX2022007989A (en) | Compositions and methods for treating pterygium. | |
| PL3673080T3 (en) | Antisense oligomers for the treatment of conditions and diseases | |
| CY1120950T1 (en) | FIBER TREATMENT | |
| IL268850A (en) | Combinations of 4-pyrimidinesulfamide derivatives with active ingredients for the treatment of endothelin-related diseases | |
| CO2017004715A2 (en) | Methods and formulations to treat vascular eye diseases | |
| BR112018005114A2 (en) | a new endolysin polypeptide | |
| IL283929A (en) | Treatment of 22q11.2 deficiency syndrome with cannabidiol | |
| MX2018008557A (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF. | |
| MX2022007436A (en) | Autotaxin inhibitors and uses thereof. | |
| MX2017014645A (en) | ALVOCIDIB PROPHARMS THAT HAVE AN INCREASED BIODISPONIBILITY. | |
| EA201692436A1 (en) | MEDICAL APPLICATION | |
| MX2021006408A (en) | COMBINATION THERAPY OF RADIOIMMUNOCONJUGATES WITH INHIBITORS OF DAMAGE AND DNA REPAIR. | |
| MX2022004143A (en) | Compound having brd4 inhibitory activity, preparation method therefor and use thereof. | |
| CR20190471A (en) | Modulators of pcsk9 expression | |
| JOP20210050A1 (en) | Modulators of pnpla3 expression | |
| IL272601A (en) | Pharmaceutical preparations for the treatment of ophthalmic conditions | |
| MX2020004666A (en) | PILOCARPINE COMPOUNDS WITH LIPOIC ACID FOR THE TREATMENT OF OCULAR DISORDERS. | |
| MX387839B (en) | LAMININ FOR USE IN THE TREATMENT OF A DISEASE, DISORDER, OR CONDITION OF THE CORNEAL ENDOTHELIUM. | |
| IL286268A (en) | Pridopidine for the treatment of mitochondrial diseases and disorders and symptoms associated with these diseases | |
| EA201892265A1 (en) | METHODS OF TREATMENT OF OPHTHALMIC DISEASES | |
| IL287704A (en) | Use of cannabidiol in the treatment of multiple sclerosis complex | |
| EA201790893A1 (en) | METHODS OF TREATMENT OF OPHTHALMOLOGICAL DISORDERS | |
| EP3592377A4 (en) | DOSAGE FORMS OF TISSUE KALLIKREIN 1 |